Viridian Therapeutics, Inc.\DE 8-K

What Happened
Viridian Therapeutics, Inc. (VRDN) filed a Form 8-K on May 5, 2026 (Item 2.02) announcing it has issued a press release reporting its financial results for the quarter ended March 31, 2026. The press release is furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 5, 2026 (Form 8-K).
• Reporting period: quarter ended March 31, 2026 (Q1 2026 quarterly results / earnings).
• Exhibit provided: Press release dated May 5, 2026 (Exhibit 99.1) containing the company’s reported results.
• Additional exhibit: Inline XBRL cover page (Exhibit 104) was included with the filing.

Why It Matters
This 8-K signals that Viridian has publicly released its latest quarterly financial results — a primary source for investors to assess recent earnings, revenue, cash position, and any management commentary or guidance. Investors should review the attached press release (Exhibit 99.1) and any subsequent filings for the specific revenue, expenses, net income/loss, cash runway, and guidance details, since those figures can affect valuation, analyst expectations, and short‑term stock movement.